Press release

TrakCel announces the appointment of industry experts Martin Lamb and Robert Margolin

Industry experts strengthen the TrakCel's industry leadership position.

CARDIFF, WALES, UK – 2 March 2017. Today, TrakCel announced that it has appointed Martin Lamb as Executive Vice President of Sales and Marketing and Robert Margolin as Vice President of Corporate Development and Strategy, further strengthening the company’s position as the leading provider of needle-to-needle cell orchestration technology to aid in the delivery of regenerative therapies.

Having held a variety of senior business development roles in leading contract development and manufacturing organisations throughout his 25-year career in the pharmaceutical and biotechnology industry, Martin brings extensive market insight and industry knowledge to TrakCel. Prior to joining the company, Martin was Director of European Business Development for Catalent Pharma Services – one of the world’s largest contract development and manufacturing organisations. During his time as Vice President of Global Business Development at the Almac Group, Martin helped the group’s clinical trial supply business grow from a niche service offering to a major business with over 1,500 staff internationally. The skills and experience Martin brings to the team will be invaluable to the success of TrakCel moving forwards.

With over 12 years of experience working in the advanced therapy and regenerative medicine sectors of the biotechnology industry, Robert brings a wealth of expertise and experience to the TrakCel team. Before joining TrakCel, Robert was Vice President of Corporate Development for Cognate BioServices, where his efforts enabled the company to evolve into one of the leading commercial-scale cell therapy contract manufacturing organisations. Robert has also previously held positions of Senior Consultant and Vice President of Communications for the Alliance for Regenerative Medicine, and has been responsible for organising the World Stem Cell Summits. Robert’s deep understanding of the industry and cell therapy manufacturing will help to ensure TrakCel continues to be positioned as an industry leader.

“We are delighted to welcome Martin Lamb and Robert Margolin to the TrakCel team,” said Ravi Nalliah, Chief Executive Officer. “The extensive industry knowledge and years of experience Robert and Martin have perfectly extends that of the company. This is an exciting time for TrakCel and we are looking forward to seeing what the future brings.”

About TrakCel 
TrakCel's software platform provides cell and gene therapy companies with a proven solution that delivers real-time control over the entire supply chain, including manufacturing, from sample collection through to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products by improving efficiency and removing complexity while maintaining compliance and traceability from needle-to-needle. 

TrakCel’s technology is increasingly being adopted by leaders in the cell and gene therapy industry. TrakCel is headquartered in Cardiff, Wales with a US office in Newport Beach, California.

Head Office
TrakCel Ltd.
11 Raleigh Walk
Brigantine Place
Cardiff,
CF10 4LN
United Kingdom

www.trakcel.com

Public Relations contact: pr@trakcel.com